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Does Administration Timing of Ondansetron, a 5-HT3 Receptor Antagonist, Affect
Inhibition of the Bezold-Jarisch Reflex in OB C-section Patients Receiving Spinal
Anesthesia
Abstract
Ondansetron (a 5HT-3 receptor antagonist) has been shown in multiple randomized controlled trials
(RCT’s) and meta-analysis to inhibit activation of Bezold-Jarisch Reflex (BJR) in response to spinal
anesthesia for elective cesarean section patients. Studies have not determined whether the timing of
administration changes the inhibitory affect of ondansetron in this patient population. This project
addressed the following question: Does administration timing of Ondansetron, a 5-HT3 receptor
antagonist, affect inhibition of the Bezold-Jarisch Reflex in obstetric cesarean section patients receiving
spinal anesthesia? De-identified aggregated electronic medical record data for a one-year period was
obtained. Data was grouped by ondansetron administration timing prior to spinal administration: ≤ 15
minutes (G1), > 15 minutes and ≤ 30 minutes (G2), > 30 minutes (G3). Blood Pressure (BP) data,
including systolic, diastolic and mean arterial pressure (MAP), was included for four time points: pre
spinal, 5-, 15- and 30-minutes post spinal. Change in BP from baseline were used for analysis. Total
vasopressor usage was also included for analysis. Sixty-six obstetric cases were included, (G1 n=24), (G2
n=24) and (G3 n=18). Data was analyzed using the one-way ANOVA test for BP change scores and the
Kruskal-Wallis for evaluating vasopressor use. No statistical significance between groups was found in
BP change scores or vasopressor use. However, G3 did show greater drops in BP and increased
vasopressor usage compared to G2 and G1. Further evaluation is recommended through either a largescale retrospective study or randomized control trial (RCT).
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Abstract
Ondansetron (a 5HT-3 receptor antagonist) has been shown in multiple randomized controlled
trials (RCT’s) and meta-analysis to inhibit activation of Bezold-Jarisch Reflex (BJR) in response
to spinal anesthesia for elective cesarean section patients. Studies have not determined whether
the timing of administration changes the inhibitory affect of ondansetron in this patient
population. This project addressed the following question: Does administration timing of
Ondansetron, a 5-HT3 receptor antagonist, affect inhibition of the Bezold-Jarisch Reflex in
obstetric cesarean section patients receiving spinal anesthesia? De-identified aggregated
electronic medical record data for a one-year period was obtained. Data was grouped by
ondansetron administration timing prior to spinal administration: ≤ 15 minutes (G1), > 15
minutes and ≤ 30 minutes (G2), > 30 minutes (G3). Blood Pressure (BP) data, including systolic,
diastolic and mean arterial pressure (MAP), was included for four time points: pre spinal, 5-, 15and 30-minutes post spinal. Change in BP from baseline were used for analysis. Total
vasopressor usage was also included for analysis. Sixty-six obstetric cases were included, (G1
n=24), (G2 n=24) and (G3 n=18). Data was analyzed using the one-way ANOVA test for BP
change scores and the Kruskal-Wallis for evaluating vasopressor use. No statistical significance
between groups was found in BP change scores or vasopressor use. However, G3 did show
greater drops in BP and increased vasopressor usage compared to G2 and G1. Further evaluation
is recommended through either a large-scale retrospective study or randomized control trial
(RCT).
Keywords: Ondansetron, Bezold-Jarisch Reflex, Spinal Anesthesia, Cesarean Section.
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Does Ondansetron as a 5-HT3 Receptor Antagonist Inhibit the Bezold-Jarisch Reflex in OB
C-section Patients Receiving Spinal Anesthesia
Hypotension and bradycardia are two of the most common side effects of spinal
anesthesia prior to cesarean section. This is due to multiple events related to the anesthetics
sympathetic blockade resulting, in part, due to activation of the Bezold-Jarisch Reflex. Current
practice dictates the use of preloading with crystalloid solution and treating
hypotension/bradycardia with vasoactive medication. Current research suggests that the use of
ondansetron, a 5HT-3 receptor antagonist, can be utilized to block this reflex pathway.
Background and Significance
Spinal anesthesia has been the gold standard of anesthetic administration for cesarean
section patients. Sensory blockade of T4 is needed to cover the surgical area involved in this
procedure. Due to this level of blockade, two of the most frequent side effects can be profound
hypotension and bradycardia.
After administration of the spinal anesthetic, the parturient patient undergoes loss of
sympathetic stimulation. The effect is a drop in systemic vascular resistance (SVR) along with
decreased venous return due to the resulting peripheral vasodilation. Reduction in venous return
results in increased cardiac hypercontraction due to decreased afterload. Mechanoreceptors in the
left ventricle are activated, which in turn causes bradycardia and hypotension due to increased
parasympathetic stimulation. This response is known as the Bezold-Jarisch reflex (BJR)
(Nagelhout & Elisha, 2018).
Maternal hypotension as a result of BJR activation can advance into certain life
threatening conditions for the baby as well as the mother. Untreated spinal induced hypotension
can lead to worsening hemodynamic instability, and potential cardiovascular collapse (Miller and
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Pardo, 2018). This can also lead to greater drops in fetal pH, as well as increased fetal base
deficits (Reynolds & Seed, 2005).
There are several approaches anesthetists utilize to treat these side effects. These
approaches include preloading/co-loading with crystalloid solution, administering intravenous
(IV) vasoactive medications, and placing the patient in the left lateral or Trendelenburg position.
Each of these approaches have been shown to mitigate these side effects (Chestnut et al., 2020).
Problem Statement
Without prophylactic management, about 80% of parturient patients receiving this type of
anesthesia will present with maternal hypotension (Ryu et al., 2019). Sustained hypotension can
lead to decreased uteroplacental perfusion which can lead to fetal hypoxia, acidosis, and neonatal
depression. Adverse maternal outcomes can include altered levels of consciousness, aspiration,
apnea, and cardiac arrest (Chestnut et al., 2020). Studies on the effects of vasopressors in this
setting are inconsistent in efficacy results (Ryu et al., 2019). Research on preload/co-load
crystalloid fluid administration has been shown to be minimally effective(Chestnut et al., 2020).
Currently there is no single intervention that “prevents” spinal induced hypotension for patients
undergoing cesarean section.
Recent studies have looked into preventing spinal induced hypotension by blocking the
BJR at the nerve receptor sites. Warltier et al. (2003) suggest the BJR is caused by activation of
5-HT3 serotonin receptors located on unmyelinated c-fibers originating in the cardiac muscle.
Yamano et al. (1995) also demonstrated through animal studies that selective 5-HT3 receptor
antagonists can help inhibit the BJR when serotonin is injected directly into the bloodstream of
rats. Through the blockade of the 5-HT3 receptor, parasympathetic response may be attenuated
to prevent hypotension. Ondansetron, a 5-HT3 antagonist routinely used for post-operative
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nausea and vomiting, can potentially be used to help block this reflex depending on the timing of
administration. Does administration timing of ondansetron, a 5-HT3 receptor antagonist, affect
inhibition of the BJR in OB c-section patients receiving spinal anesthesia?
Literature Review
Methods
Databases used for literature search included “PubMed” and “Franklin Database”. Search
phrase consisted of “Ondansetron and spinal anesthesia and hypotension” for each database. The
“and” in both database searches were Boolean operators.
The PubMed search resulted in 38 articles found. Search was narrowed to within the last
8 years (2012-2020). Thirteen publications were excluded due to being unrelated to
administration of ondansetron pre-spinal anesthesia. Twenty-five publications were retained for
further review based on inclusion criteria of drug used (ondansetron), administration prior to
spinal anesthesia, and hypotension. See Figure 1 for PRISMA diagram.
The Franklin Database search was narrowed to peer reviewed publications only, and
publications within the last 10 years (2010-2020). One hundred results were found using this
method. Database delimiter words consisted of analgesia, analgesics, analgesic opioid
administration and dosage, analgesic opioid adverse effects, analgesics opioid therapeutic use,
clonidine, dexamethasone, dexmedetomidine, fentanyl, ketamine, laparoscopic surgery,
laparoscopy, male, morphine, narcotics, nausea, opioids, pain, pain management, pain
measurement, pain medicine, pain postoperative, pain postoperative drug therapy, pain
postoperative prevention and control, patient satisfaction, postoperative analgesia, postoperative
nausea, postoperative nausea and vomiting prevention and control, postoperative pain,
postoperative period, propofol, ropivacaine, shivering, and vomiting. The PubMed database was
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then excluded in the Franklin search criteria due to already being searched as stated above. Fiftyseven publications were found according to the new criteria. Publications were screened and 53
were excluded for relevancy due to being unrelated to administration of ondansetron pre-spinal
anesthesia. Six of the publications were retained for review based on inclusion criteria of drug
used (ondansetron), administration prior to spinal anesthesia, and hypotension.
Four publication duplicates were found and removed between the two database results.
This resulted in 27 full-text articles assessed for full eligibility criteria. Publications were then
excluded due to the type of drug used (not ondansetron 5HT-3 receptor antagonists), surgery
performed (not cesarean section), crystalloid co-administration, vasopressor co-administration,
study sample size less than 50, weight-based dosing of ondansetron, and date of publication prior
to 2014. Ten publications were included in this review.
Data Evaluation
The Consort 2010 checklist (Moher, 2010) was utilized for evaluating the quality of the
randomized controlled trials (RCT’s). The Center of Evidence Based Medicine (CEBM)
checklist (University of Oxford, 2020) was utilized for evaluating the meta-analysis and
systematic reviews. The Johns Hopkins Evidence Level and Quality Guide (Dang & Dearholt,
2018) was also utilized for grading the quality of all studies evaluated.
Consort 2010 provides a checklist of RCT-specific elements that should be included in all
trials. The checklist contains 25 items that appraise the title and abstract, introduction, methods,
results, discussion, as well as other information related to the study. Upon appraisal using this
checklist, the studies were then assigned a level of evidence (1-5), and a quality of evidence (A,
B, or C) using the Johns Hopkins Evidence Level and Quality Guide (Dang & Dearholt, 2018).
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The CEBM (University of Oxford, 2020) was used to evaluate the meta-analysis and
systematic reviews. This tool asks a series of six questions evaluating the question presented, the
relevancy of the study, inclusion/exclusion criteria, the validity of the included studies and the
similarity of results from study-to-study. The studies were then assigned a level of evidence (15), and a quality of evidence (A, B, or C) using the Johns Hopkins Evidence Level and Quality
Guide (Dang & Dearholt, 2018).
Results
Ten studies were included in the review and evaluated. All studies investigated the
administration of ondansetron at five minutes prior to spinal administration. Six of the studies
were RCTs and four were meta-analyses (See Table 1).
Mareshi et al. (2014) found that administering 6mg and 12mg of IV ondansetron
significantly attenuated spinal induced hypotension. They also found an increased requirement
of vasopressors in the control group compared to the experimental group (p=0.04). Shabana et al.
(2018) administered 4 mg of ondansetron IV to an experimental group, and found drops in
arterial blood pressures were significantly reduced (p=0.007) and required less vasopressor
medication compared to the control group (p=0.005). Trabelsi et al. (2015) concluded patients
who received ondansetron in the experimental group prior to spinal administration experienced
decreased amounts of hypotension (p<0.001) compared to the control group. Vasopressor usage
was also significantly decreased (p≤0.001) in the experimental group. Wang et al. (2014)
evaluated different dosing of ondansetron in experimental groups. The findings suggested
patients who received 4 or 6mg ondansetron experienced significantly reduced incidences
(p≤0.05) of hypotension. Those that received 2 or 8mg ondansetron were observed to experience
only minimal decreases (p≥0.05) in hypotension compared to the control group.
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Tatikonda, et al. (2019) and Ortiz, et al. (2014) found non-significant results regarding
ondansetron affect on hypotension. Ortiz, et al. (2014) found no significant difference for
hypotension between the placebo and ondansetron groups (p=0.77). The authors attributed their
results to the use of fentanyl in the spinal administration which may have led to more
pronounced hypotension. This study excluded any patient with a BMI over 30 kg/m2, which may
have limited the study to a specific population different from other studies included in the
review. Further, the results may be less representative of the general c-section population.
However, this study did show that the need for vasopressor use was decreased after
administration of ondansetron, which does illustrate a benefit of ondansetron usage. Tatikonda,
et al. (2019) demonstrated similar results in that blood pressure was not significantly affected (p
> 0.05) by ondansetron, but vasopressor usage was lower in the experimental group compared to
the control group (p=0.029).
Three meta-analyses examined in the literature showed that the prophylactic use of
ondansetron can help alleviate spinal anesthesia induced hypotension. Tubog, et al. (2017)
evaluated nine RCT’s (N= 984) specifically involving parturient patients receiving spinal
anesthesia for cesarean section. Five of the RCTs showed decreased hypotension and pooled data
results showed ondansetron did attenuate hypotension in the parturient patient groups (RR 0.63;
CI, 0.45-0.88). Gao, et al. (2015) included six obstetric RCTs (N=452) where ondansetron was
given prior to spinal administration. Gao, et al. (2015) findings suggest that ondansetron reduced
hypotension (RR=0.47; 95% CI 0.35-0.63) caused by spinal anesthesia administration as well as
decreased ephedrine use (-2.35mg; 95% CI –4.14, –0.55mg) and phenylephrine (-31.16 mcg;
95% CI -57.46, –4.87 mcg). Heesen et al. (2016) evaluated seven RCTs of obstetric patients
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(N=706). Findings suggested that ondansetron was effective (RR 0.70; 95% CI 0.49-0.99) in
reducing hypotension in parturient cesarean section patients.
Zhou et al. (2018) evaluated 21 RCTs of parturient patients undergoing cesarean section.
Only five of these RCTs evaluated hypotension specifically (N=362). Their analysis did not
show a significant difference in hypotensive response (RR=0.72; 95% CI 0.50, 1.06) during
spinal anesthesia. While this study pooled more RCTs compared to the other three metaanalyses, it also had the smallest sample size in regard to hypotension. The study included with
the highest risk ratio presented was also dated from 1999 and the aim of the study was not
evaluating ondansetron dosing prior to spinal administration. Instead, ondansetron was given
intra-op and post spinal anesthesia induction.
Across the included studies, there was consistency in results for the significant reduction
of hypotension with ondansetron administration prior to spinal anesthesia in c-section patients.
This was similarly affirmed in the included meta-analyses. The strength and quality of evidence
is highly supportive of the positive effects of ondansetron for reducing or limiting the untoward
side effects of spinal anesthesia in c-section patients. There remains a gap in available trials
regarding the timing of ondansetron administration relative to spinal anesthesia.
Organizational Assessment
Protocol at the project site, a large medical center in a suburban area, dictates that 4 mg
ondansetron is administered prior to all elective cesarean sections receiving spinal anesthesia for
patients with no contraindications. Timing of administration is not standardized at the site.
Administration timing varies from 5 minutes to an hour prior to the procedure start. Whether this
alters the positive effects of ondansetron on the hypotensive response from spinal anesthesia is
not well known.
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The project stakeholders included the IT department for data abstraction, CRNA site
lead, DNP faculty lead, and site nurse educators. Other stakeholders included the anesthesia
providers and hospital administration in providing safe quality care, founded on evidence-based
practice.
Project Purpose
This retrospective study explored the effects of ondansetron administration timing on
spinal anesthesia hypotension in cesarean section patients at the site. While the use of
ondansetron in the prevention of spinal induced hypotension has been studied and is efficacious
with pre-spinal administration at 5 minutes, the site’s standard of practice for administering
ondansetron does not define timing of administration. The goal was to determine through a
retrospective analysis of existing data if ondansetron administration timing affects hypotension
and the amount of vasopressor usage in this patient population. These results will inform a
standardization of practice in accordance with ondansetron delivery timing at the site.
Conceptual and Theoretical Framework
Conceptual Framework
For this project, the Stetler Model was chosen for the conceptual framework. The Stetler
Model is used to judge “appropriateness, desirability, feasibility, and manner of using research
findings” according to Stetler (2001). This model involves steps that include the evaluation of
research to help determine evidence-informed practice. These steps are broken down into five
different phases for the development and revision of standards of nursing practice.
Stetler’s first phase is considered the preparatory phase. In this phase the project purpose
and outcomes are defined. Affirmation of priority, consideration of influential factors, and
review of current literature is also taken into consideration (Stetler, 2001). This project is focused
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on determining if the delivery of ondansetron reduces spinal induced hypotension in patients
receiving spinal anesthesia in elective cesarean sections. This is a priority because hypotension is
a common side effect of spinal anesthesia and is associated with poor maternal and fetal
outcomes (Chestnut et al., 2020). Research literature regarding ondansetron use to prevent
maternal hypotension due to spinal anesthesia for elective cesarean section patients was reviewed
and synthesized for the project.
Stetler’s second phase of validation includes the critique and synopsis of the literature
and determining whether the evidence is subject to rejection. The literature review on this subject
was conducted and the findings support this practice (Table 1). The overall level and quality of
the evidence of the studies evaluated ranged from 1A to 1C using the Johns Hopkins Evidence
Level and Quality Guide (Stetler, 2001).
Phase three is defined as comparative evaluation and decision making. During this phase,
four major items are assessed before a decision is made to move forward with the project. The
fitness of the setting, the feasibility, current practice, and substantiating evidence are all
evaluated. There is substantial evidence to support the evaluation of the use of ondansetron in
this practice setting. The setting of this project is Atlanticare obstetric unit where current practice
dictates the administration of ondansetron prior to all cesarean section procedures. This project
will evaluate de-identified data which will require few resources and have minimal to no impact
on daily operations at this site. Based on the criteria laid out in phase three of the Stetler Model,
the decision can be made for this project to move on to phase four (Stetler, 2001).
Phase four of Stetler’s model is where the results are translated and implemented for the
project. In this retrospective study, de-identified data will be provided by the site IT department
of elective cesarean section patients undergoing a spinal anesthetic. There are three ways of
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implementation, direct instrumental, cognitive, and symbolic use. For this project, cognitive use
will be employed to better understand and appreciate the relationship of ondansetron
administration, specifically the timing of the dose, and hypotension in spinal anesthesia. The
method will also be considered in relation to informal/formal and direct/indirect. This project
will be considered formal with indirect evaluation of aggregate patient data. This will require
IRB approval prior to implementation (Stetler, 2001).
Phase five of Stetler’s model is the evaluation phase. During this phase, the data can be
evaluated in a formal/informal manner and can be accomplished on an individual or institutional
level. This project will consider a formal evaluation at the institutional level. Evaluation of the
data will review actual implementation and results of the project, while also summarizing phase
one outcomes and goal results (Stetler, 2001). This phase concludes with official decisions on
either a new best practice or continuation with the current status quo based on the results.
Theoretical Framework
The theoretical framework for this study is the Theory of Unpleasant Symptoms (TOUS).
TOUS involves three major concepts. These concepts consist of symptom(s) of the patient,
influencing factors, and performance outcomes (Smith & Liehr, 2013)
The symptoms concept is identified by four different areas. These areas consist of timing,
intensity, quality, and distress. Spinal induced hypotension is an objective symptom which is
associated with a variety of subjective symptoms. These symptoms can include nausea,
vomiting, dizziness, and dyspnea (Miller & Pardo, 2018). The timing, intensity, quality and
distress can vary depending on the severity of hypotension as well as how quickly it is treated.
The influencing factors are broken down into three distinct categories. Physiological,
psychological, and situational factors make up these categories (Smith & Liehr, 2013). This
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study aims to alter the physiological factor associated with the symptom of spinal hypotension.
This will be accomplished through the evaluation of using ondansetron to avoid the
physiological factor of hypotension from spinal anesthesia.
Performance outcomes can involve the impact of the symptom on the patient's ability to
function physically (Smith & Liehr, 2013). Regarding this project, not only does this ability to
function affect the patient, but it can also affect the baby as well. As stated above, untreated
spinal induced hypotension can lead to worsening of symptoms and potential cardiovascular
collapse in the parturient (Miller & Pardo, 2018). This can also lead to unwanted fetal side
effects (Reynolds & Seed, 2005).
Methods
Setting
The site's OB department was the setting for this project. The site is a general medical
and surgical facility that provides care to an underserved population. The OB department has 10
inpatient beds, four triage rooms, and two OR suites available. The site is also considered a
teaching hospital and performs an estimated 900 cesarean sections a year.
Participants
Aggregate data was abstracted and de-identified by the site IT Dept. for all full-term
maternal patients who have undergone elective cesarean section and received prophylactic
ondansetron prior to spinal anesthesia. Exclusion criteria included all patients who underwent
non-elective/emergent cesarean section, who received continuous phenylephrine infusion, and
who did not receive spinal anesthesia. Aggregate de-identified data included cases during a oneyear time frame (01/01/2020 – 12/31/2020) that meet the criteria.
Intervention
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The retrospective data analysis evaluated the timing of administration of ondansetron and
how it directly affects post-spinal anesthesia BP change scores and total vasopressor usage. Data
at the patient level that was eligible for analysis was categorized into one of three groups based
on the timing of ondansetron administration in relation to spinal administration. Aggregate deidentified data was provided by the site IT department.
Project Implementation
Institutional Review Board (IRB) approval was obtained from The University of
Pennsylvania and from Atlanticare. A request to the site IT department for de-identified data
abstraction was placed with the following parameters. Inclusion criteria, all anesthesia records
and medication administration records (MAR) data for scheduled cesarean sections during the
year 2020. Exclusion criteria, all non-elective or emergency cesarean sections, patients who
received a phenylephrine drip/infusion, patients who did not receive prophylactic ondansetron,
patients who have an allergy to ondansetron, patients who did not receive spinal anesthesia. Data
requested included timing of prophylactic ondansetron administration, timing of spinal
administration, patient demographics including age, race, ethnicity, weight, height, BMI, patient
health history, blood pressure values at four specific time periods (pre-spinal administration
blood pressure, 5,15,and 30 minutes post spinal), total ephedrine and phenylephrine used for the
procedure.
De-identified Variable Data
The independent variable for this project was the timing of ondansetron administration
prior to spinal anesthesia administration. Administration timing was categorized as follows:
Group one (G1) was ondansetron administration ≤ 15 minutes of spinal administration; Group
two (G2) was ondansetron administration > 15 minutes and ≤ 30 minutes of spinal
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administration; Group three (G3) was ondansetron administration > 30 minutes from spinal
administration.
The formula for categorizing the independent variable was: [spinal administration time –
ondansetron administration time]. Upon determination of total time between procedures, patient
level data were placed into one of the three groups accordingly.
There were two dependent variables evaluated in this project. The first dependent
variable was blood pressure, pre- and post-spinal administration. The second dependent variable
was the total amount of vasopressor usage during the procedure.
Blood pressure value data from four different time periods was included, including values
for systolic BP, diastolic BP, and mean arterial pressure. The first time period was blood pressure
value prior to spinal administration (baseline). The second BP value was five minutes post spinal
administration. The third BP value was at 15 minutes post spinal administration. The fourth BP
value was at 30 minutes post spinal administration.
Total vasopressor usage data (ephedrine and phenylephrine) was included for the entire
procedure. Phenylephrine was presented in microgram (mcg) totals. Ephedrine was presented in
milligram (mg) totals.
Other de-identified data presented included demographics and patient characteristics.
This included age, race, ethnicity, weight, height, BMI, and patient health history with a focus on
preeclampsia, gestational diabetes, and hypertension.
Data from the site was initially evaluated for errors and contained 298 patients. Of the
298 patients, 222 were excluded due to receiving a phenylephrine infusion leaving 76 patients.
Three patients were excluded for being emergency cesarean sections leaving 73 patients. Seven
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patients were excluded for not receiving ondansetron prior to spinal administration leaving 66
patients contributing data for the analysis.
Pre-spinal MAP data was not included in the data received but pre-spinal BP was
provided. Pre-spinal MAP was therefore calculated by the equation (0.333*(pre-spinal systolic
blood pressure - pre-spinal diastolic blood pressure) + pre-spinal diastolic blood pressure).
Data Management
The de-identified data in excel from the site IT Dept. was stored on Matthew Rowley’s
University of Pennsylvania’s School REDCap account. Access was available to authors as well
as DNP faculty members involved in this project. De-identified data had a random identifier
number randomly assigned to each data row representing a single patient in the dataset.
Data was kept on the secure REDCap server for long-term storage. Data will be stored
until analysis and dissemination of the results or until August 30, 2021. Data will then be
destroyed.
Analysis
Descriptive statistics were used to summarize blood pressure measurements, vasopressor
use, and patient characteristics. Blood pressure measurements were measured in mean and
standard deviations, demographics were measured in frequency, mean and standard deviation.
Data was evaluated for normality using box plots and the Shapiro-Wilk test for normality via
SPSS Inc. (Version #27, IBM). Ephedrine and phenylephrine totals did not show normality,
while most changes in blood pressure did. Upon confirmation of a normal distribution and
absence of outliers, blood pressure change scores were used to calculate the one-way ANOVA.
For blood pressure change scores that were not found to have normal distribution the KruskalWallis was used instead. Change scores were calculated by subtracting the post-spinal blood
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pressure values from the pre-spinal blood pressures. The separate tests determined the
significance value of the independent variable groups (time of ondansetron administration) and
each dependent variable (blood pressure changes scores). Dependent variables were each
evaluated independently (Laerd statistics, 2017) between the groups. Vasopressor data was found
to not be normally distributed, thus the Kruskal-Wallis test was utilized (Laerd statistics, 2017).
Analysis also included statistical evaluation of the demographic data. This included the
mean and total number for each group. This evaluation helped to conclude whether the three
groups were similar demographically (Laerd statistics, 2017).
Results
Group Description
An aggregate data set was used for the project that included data from 66 records. Groups
included women with mean age of 31 years, predominantly white (40.9% [n=27]) and African
American (31.8% [n=21]). The group was predominantly non-Hispanic (80.3% [n=53]). The
total group ASA status was 74.2% ASA II, 24.2% ASA III, and 1.5% ASA I (See Table 2).
Records were grouped by Ondansetron administration timing to form group level data for
the analysis. For detailed demographic descriptions see Table 2. Patients were placed into 3
groups: ondansetron administration ≤15 minutes (n=24), ondansetron administration >15 or ≤ 30
minutes (n=24) and ondansetron administration >30 mins (n=18).
One-Way ANOVA/Kruskal-Wallis for Changes in BP
A one-way ANOVA test was done to determine if the delivery timing of ondansetron had
an effect on change in blood pressure. Test results are presented based on the F test statistic value
and equivalent p-value. Overall, there were no statistically significant differences in change in
blood pressure outcomes based on timing of ondansetron administration. The Kruskal-Wallis test
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also showed no significant difference between the groups that were not normally distributed. See
Table 3 for a complete list of values between groups. See table 5 for a complete list of blood
pressure descriptives.
Kruskal-Wallis Test
A Kruskal-Wallis test was done to determine if the delivery timing of ondansetron had an
effect on vasopressor usage. Visual inspection of boxplots show that distributions for both
phenylephrine and ephedrine were not similar. The mean rank was not statistically significant for
total ephedrine x2(3) =1.706 p = .426 and phenylephrine x2(3) = 5.739 p = 0.57 (Table 4). See
Table 6 for average vasopressor totals.
Discussion
Summary
Although no significant values were found in the results of the data, there were notable
differences in the results between the groups regarding changes in BP and Vasopressor usage.
Overall changes in systolic, diastolic, and MAP showed G1 with the lowest decrease in BP in
every time period except for 15 minutes post spinal, in which G2 had a higher systolic and MAP.
G3 change scores were higher in all categories across all three time periods.
No significant values were found in the results of the Kruskal-Wallis test on vasopressor
usage, however notable differences between the groups were seen. Average ephedrine usage was
higher in G3 compared to G1 and G2. Similarly average phenylephrine administration was also
higher in G3.
While overall results were considered not significant, the noted differences between the
three groups is apparent. G3 had increased change/drop in BP over all 3 time periods compared
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to G1 and G2. G3 also had the highest average vasopressor usage compared to G1 and G2. This
is likely due to the drop in ondansetron peak plasma concentrations over time.
Peak plasma concentrations of 4mg of zofran after 5 minutes is around 65 ng/ml (EMC,
2020). Peak plasma concentrations drop to about 42.9 ng/ml after 10 minutes from IV
administration (PDR, 2021). As time between administration of zofran and spinal administration
increases, peak plasma concentrations of zofran are expected to decrease. The affects of zofran
on inhibition of the BJR are likely to diminish, which may explain why G3 had greater average
changes/drop in BP and increased average vasopressor usage compared to G1 and G2.
Limitations
Although results point toward ondansetron having a more positive affect in G1 and G2
limitations of this study may have affected statistical significance. These project groups
consisted of smaller sample sizes and were not perfectly equal in number. Further projects may
benefit with larger sample sizes per group as well as equal group numbers.
Another limitation that this project did not take into consideration is the average amount
of crystalloid administered per group. Differences in crystalloid amount may have altered BP
results per group in either direction. This may have had unknown effects on our results.
This project consisted of a retrospective de-identified data analysis. Further studies into
this phenomena would benefit from RCT’s to gain a better understanding of the affects of
ondansetron on BP and vasopressor usage. An RCT would be the optimal study design to answer
this question.
Implications for Practice/Policy
At this time our project cannot recommend a policy change for this site due to the lack of
statistically significant results. However, positive benefits of administering ondansetron within
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30 minutes of spinal administration can be seen in the data. This project does recommend further
exploration of benefits either through a larger scale retrospective data analysis or through a
research based RCT. Due to the vulnerable population at hand, aggregation of data from multiple
hospitals would be recommended over utilizing a RCT.
Further studies into this subject could be a benefit to this site. Considering the results of
the data, administering ondansetron within 30 minutes may not only provide higher quality
patient care, but could also result in higher cost efficiency as well. Lower average vasopressor
usage could lower cost while also improving maternal/fetal outcomes through improved
homeostasis of the mother.
Opportunities for Sustainability
Continued sustainability is dependent on further studies and analysis into the effects on
the timing of ondansetron in relation to spinal anesthesia for cesarean section. Due to the lack of
statistical significance in the results presented, no recommendation can be made for
sustainability at this time. As stated before, this project would recommend further evaluation and
larger scale studies into this subject.
Conclusions
This project evaluated through retrospective analysis of de-identified data the change in
BP and total vasopressor usage of patients receiving ondansetron at different times in relation to
spinal administration for cesarean section patients. Results of data analysis did not show
statistical significance. However, differences between the groups are noted with G3 having
greater changes/drops in average systolic, diastolic, and MAP along with increased average
vasopressor usage compared to G1 and G2. Further investigation is recommended for this site to
either evaluate a larger population in a retrospective study or conduct a RCT. Through further
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evaluation, improved timing of ondansetron could result in improved homeostasis of the
mother/infant as well as lower cost of care.
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Figures
Figure 1. PRISMA
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Figure 2. Stetler Model
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Figure 3. Theory of Unpleasant Symptoms

Reprinted with permission from Smith, M. J., & Liehr, P. R. (Eds.). (2013). Middle range theory for nursing: Third edition. ProQuest
Ebook Central https://ebookcentral-proquest-com.proxy.library.upenn.edu
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Descriptives
Figure 3 Process Flow Chart
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Tables
Table 1. Table of Evidence
Citation or Study
Number

Research Aim,
Question,
Hypothesis

Setting, Sample, and
Sampling

Design

Gao et al., 2015

To investigate
the effects of
prophylactic
Zofran on
hemodynamic
changes
following spinal
anesthesia.

Medline, Embase,
Cochrane Library
Databases searched
for RCT’s. 10 RCT’s
6 of which were OB
only. 863 patients
included.

Meta-Analysis

Heesen et al., 2016

To determine
whether 5-HT3
receptor
antagonists,
administered
before the
initiation of
spinal anesthesia,
mitigate
hypotension.

PubMed, Embase,
CINAHL, LILACS,
CENTRAL,
Clinicaltrials.gov, ISI
WOS., randomized
placebo-controlled
double-blind trials
studying preventive
effect of 5-HT3
receptor antagonists
included. Random
effects model applied,
risk ratio, weighted

Systematic
Review and
Meta-analysis
and metaregression.

Variables and
Measures

Independent =
Zofran,
Dependent
variable =
hypotension.

Independent =
Zofran 2-12mg,
Dependent
variable =
hypotension.

Findings

Level
of
Eviden
ce

Conclusions

Prophylactic zofran reduced
incidence of spinal anesthesiainduced hypotension in
OB/non-OB.
RR (relative risk) 0.53 (95% CI
0.32 - 0.86) in OB, 0.16 (95%
CI 0.05 to 0.51) non OB.
Doses of Ephedrine and
Phenylephrine required to treat
hypotension reduced by zofran
with mean differences -2.35mg
(95% CI -4.14 to -0.55mg) and
-31.16 μg (95% CI -57.46 to 4.87 μg).

Level
IA

Results suggest prophylactic
Zofran can alleviate hypotension,
bradycardia, n/v caused by spinal
anesthesia and reduce the amount
of vasopressor drugs required.

Prophylactic 5-HT3
administration significantly
reduced risk of hypotension in
combined analysis of 17 trials.
RR 0.54 (95% CI 0.36-0.81, I2
-79%). In OB trials RR was
0.52, 95% CI 0.30-0.88, I2 87% (NNT 4). Non-obstetric
studies 95% CIs were wide and
included a clinically relevant
reduction in risk of
hypotension (RR 0.50, 95% CI
0.22-1.16, I2=66%). Contour-

Level
1A

5-HT3 antagonists are effective in
reducing incidence of hypotension
and bradycardia; effects are
moderate and are only significant
in subgroup of patients
undergoing C-section. Effects in
non-OB population not
significant.
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mean difference with
95% confidence
interval (CI)
calculated. Primary
outcome incidence of
hypotension.
17 trials and 1604
patients.

Marashi et al.,
2014

To investigate
the effect of
intravenous
administration of
zofran, which
could attenuate
spinal-induced
hypotension,
bradycardia, and
shivering.

210 patients aged 2050 years scheduled for
spinal anesthesia.
Randomly divided
into 3 equal groups.
Control group = NS,
6mg zofran group,
12mg zofran group 5
minutes before spinal
anesthesia.

enhanced funnel plots
confirmed publication bias.
Meta-regression showed
significant zofran dose
response in non-OB-only
patients (β = -0.355, P=0.4). In
combined and in OB-only
analysis risk of bradycardia
significantly reduced as was
use of phenylephrine
equivalents.
Randomized
controlled trial.

Independent =
zofran
administration
6mg and 12 mg.
Dependent =
MAP, HR,
shivering
recorded
before/after
spinal anesthesia
q 5 minutes
during first 20
minutes surgery.

HR statistically different
between experimental and
control groups. 10 (14%) in
control group had HR < 50
bpm requiring IV atropine
compared to experimental
group (P=0.02). In control
group 12 (17%) patients had
MAP < 80 mm Hg requiring
vasopressors compared to
experimental groups (P=0.04).
No significant difference in
MAP and HR between
experimental groups (P=0.06).
Incidence of shivering in
control group 45% (32.70)
statistically more than
experimental group (P=0.02).

Level
1A

Administration of 2 different
doses of IV Zofran 6mg/12mg
significantly attenuates spinal
induced hypotension, bradycardia,
and shivering compared to a
control saline group.
Hemodynamic profiles/shivering
in the 2 experimental groups were
not statistically different.
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Ortiz-Gómez et al.,
2014

To study the
effect of
different doses of
Zofran in
obstetric
patients.

Double-blind,
randomized, placebocontrolled study, 128
healthy pregnant
women scheduled for
elective caesarean
delivery, under spinal
anesthesia.

Randomized
Controlled
Trial

Independent
variable = 4
different Zofran
doses 2/4/8mg
and placebo.
Dependent
variable =
hypotension.
Demographic,
OB,
intraoperative
timing and
anesthetic
variables
assessed at 16
time points (BP,
HR, O2 sat, n/v,
ECG changes,
skin flushing,
discomfort,
pruritus,
vasopressor
requirements.

No difference in number of
patients with hypotension in
placebo (43.8%), Zofran 2mg
(53.1%), 4mg (56.3%), 8mg
(53.1%) groups (P=0.77),
neither the percentage of time
points with systolic
hypotension (7.3% placebo,
2mg 11.1%, 4mg 15.7%, 8mg
12.6%.) No differences
between groups in ephedrine
(P=0.11) or Phenylephrine
(P=0.89) requirements and the
number of patients with
adverse s/e. Difference in
ephedrine dosing amount was
noted in chart...

Level
1B

Prophylactic zofran had negligible
effect on incidence of hypotension
in healthy parturients undergoing
spinal anaesthesia with
bupivacaine and fentanyl for
elective caesarean delivery.

Shabana et al.,
2018

To evaluate the
efficacy of
zofran during
spinal anesthesia
for c-section in
overcoming the
associated n/v,

100 parturients
scheduled for elective
cesarean section
randomly allocated
into two groups.
Group 1 Zofran 4 mg,
Group 2 received NS.

Prospective,
RCT, double
blind study.

Independent
variable = 4mg
zofran.
Dependent
variable = BP,
HR, n/v,
shivering,

Decreases in systolic arterial
pressure were significantly
lower in group 1 then group 2.
Group 1 had significantly less
requirement for vasopressors
(P= 0.005). needed lower dose
of vasopressor (P=0.01), and

Level
1A

Conclusion in parturient women
undergoing elective cesarean
section, intravenous 4mg zofran
significantly decreased the
hypotension, HR fluctuation, and
vasopressor doses used.
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bradycardia, and
hypotension.

vasopressor
requirements,
Apgar score at 1
and 5 min.

lower incidence of n/v
(P=0.03). Decrease in HR was
significantly lower in group 1
then Iafter spinal anesthesia
administration) at 20 min , and
50 min Decrease in MAP
lower in group I then II just
after spinal anesthesia.
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Tatikonda et al.,
2019

To study the
effect of IV
ondansetron on
hypotension and
bradycardia
induced by
spinal anesthesia.

140 ASA class I-II
patients that were
scheduled for
infraumbilical surgery
were assigned into
two groups by a
computer-generated
random number table

Double Blind
RCT

IV- Ondansetron
DVHypotension,
bradycardia, and
shivering

Four patients in Group B and
no patients in Group A
experienced bradycardia

IA

Prophylactic use of ondansetron
reduced the need for ephedrine in
patients receiving spinal
anesthesia, and did not have an
effect on bradycardia.

IB

Study showed that prophylactic
ondansetron had a significant
effect on the incidence of
hypotension in healthy parturients
undergoing spinal anaesthesia

No difference in
hemodynamics (SBP, DBP,
and MAP) between both Group
A and B
19 patients in Group A and 33
in Group B required ephedrine
with

Trabelsi et al.,
2015

Investigate the
use of IV
ondansetron for
prophylaxis of
hypotension after

80 ASA class I
primapare parturients
undergoing caesarean
section were
randomly assigned to

Double blind
RCT

IV- Ondansetron
DVHypotension

Less patients in the
ondansetron group experienced
hypotension as compared to
those in the S group: 15
(37.5%) and 31 (77.5%)

35

spinal anesthesia
in parturients
scheduled for
elective
caesarean section
and its
consequences on
newborn
parameters

two groups using a
computer generated
random sequence

(P<0.001). Thus, the average
consumption of ephedrine
intraoperatively was 5.10 +
7.78 mg in group O while it
was 12.90 + 9.27mg in group S
with a significant difference .

with bupivacaine and sufentanil
for elective caesarean delivery.

Bradycardia was seen in 6
patients in the ondansetron
group, and was more frequent
in the saline group,15 cases,
Atropine administration in
group S was 0.12 + 0.22mg.
Yet, no atropine was required
in group O.
Apgar scores in group O were
higher than those in group S

Tubog et al., 2017

The purpose of
this review is to
conduct a
comprehensive
meta-analysis of
randomized
controlled trials
(RCTs) using
intravenous (IV)
ondansetron in
reducing the
incidence of

Literature search
included MEDLINE,
Google Scholar,
CINAHL, and The
Cochrane Review
Database.
RCTs of prophylactic
ondansetron (any
dose) vs placebo or
other interventions
administered before

A Systematic
Review and
Meta-Analysis

IV-Ondansatron
DVHypotension and
bradycardia

Bradycardia. 11 of the 13
RCTs had patients that
experienced bradycardia in the
placebo group, the treatment
group or groups, or both. Two
of the 13 studies reported
statistically significant
differences. Marashi et al. and
Trabelsi et al. saw attenuation
of spinal anesthesia-induced
bradycardia in patients that
received ondansetron. One of

1A

The results support the hypothesis
that administration of IV
ondansetron, 5 minutes before the
placement of local anesthetic into
the subarachnoid spa, helps to
attenuate SIH and bradycardia
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hypotension and
bradycardia
associated with
spinal anesthesia

Wang et al., 2014

Compare the
efficacy of
different doses of
ondansetron
preloading
combined with
rapid crystalloid

neuraxial blockade, in
all types of surgery
that use spinal
anesthesia as the
primary anesthetic
technique were
included.

these studies evaluated 6-mg
and 12-mg doses, and the other
study assessed a 4-mg dose.
Meta-analysis of the pooled
data showed that ondansetron
reduced the risk of bradycardia
by a relative 69%

MESH terms:
ondansetron,
hypotension, spinalinduced hypotension,
maternal hypotension,
bradycardia, and
spinal anesthesia

Maternal Hypotension. Nine
RCTs reported the incidence
of hypotension during elective
cesarean delivery. Of these, 5
studies showed a significant
reduction in hypotension
compared with placebo. Pooled
analysis of the 9 RCTs showed
that IV ondansetron attenuated
maternal hypotension
Heterogeneity was lower
compared with the allprocedure meta-analysis I2 =
68% vs. I2 = 73%.
Four trials in the nonobstetric
setting looked at the
administration of IV
ondansetron before spinal
anesthesia. The pooled data
showed that pretreatment of IV
ondansetron was not associated
with a decrease in the
incidence of hypotension.

150 ASA class I-II
primiparous and
parturient women
were selected at the
Wuxi Maternal and
Child Health Hospital.
Participants were

Double-blinded
RCT

IV
Ondansetron
administration of
2mg, 4mg, 6mg,
8mg
DV

Compared with group S, the
incidence of maternal
hypotension was obviously but
not significantly reduced in
groups O2 and O8 , but
significantly reduced in groups
O4 and O6

IB

Prophylactic administration of 4
mg of ondansetron was the
optimal dose to prevent
hypotension during cesarean
delivery.4
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Zhou et al., 2018

coloading on
reducing
maternal
hypotension
during cesarean
delivery. Also
assessed the
effects of
different doses of
ondansetron
preloading on
maternal nausea,
umbilical venous
pH, partial
pressure of
carbon dioxide
(Pco2),
bicarbonate
(Hco3 -) and
base excess in
extracellular
fluid (BEecf),
and neonatal
outcome after
delivery.

randomly assigned to
one of five groups
using computer
generated codes.

To investigate
the efficacy and
safety of
ondansetron
during cesarean
section under
spinal anesthesia

The Cochrane
Library, PubMed,
MEDLINE, and Web
of Science were used
to search for RCTs
where ondansetron
was given for spinal
anesthesia for
cesarean section.

Hypotension,
maternal nausea,
umbilical venous
pH, PCO2,
HCO3 and base
excess in
extracellular
fluid and
neonatal
outcome after
delivery

The incidence of nausea in
groups O2, O4, O6, and O8
was significantly lower than
that in group S (P < 0.05)
No bradycardia or vomiting
were observed in groups O4,
O6, and O8, while one and two
women in groups S and O2 had
bradycardia or vomiting
The use of phenylephrine in
group O4 was significantly less
than that in group S
There were no significant
differences in Apgar scores at 1
and 5 min after delivery or
birth weight among the five
groups
The gas analysis results
showed that there were no
significant differences in pH,
Pco2, PO2, Hco3 -, or base
excess

Meta-Analysis

IV- Ondansetron
DVHypotension

21 RCTs were used. Metaanalysis showed that
ondansetron group had a
decreased rate of
nausea/vomiting P<0.00001
and bradycardia P=0.006 than
the placebo group during
cesarean section under spinal
anesthesia]. There were no

1C

Ondansetron can effectively
reduce the incidences of nausea,
vomiting, and bradycardia during
spinal anesthesia for cesarean
section, and its safety is relatively
good. Because of the small sample
size of this study, this conclusion
remains to be confirmed by
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Search terms included
“randomized
controlled trial,”
“controlled clinical
trial,” “cesarean
section,”
“ondansetron,”
“epidural,” “spinal”

differences of pruritus,
hypotension (N=362), or
shivering during cesarean
section while under spinal
anesthesia (RR=0.92, 95% CI
(0.83, 1.02), RR=0.72, 95% CI
(0.50, 1.06), and RR=0.89,
95% CI (0.71, 1.11).

studies with a larger sample size
and multi-center studies.
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Table 2. Demographic Data
DEMOGRAPHIC STATISTICS
G1 (n=24)

AGE (MEAN/SD)

G2 (n= 24)

G3 (n=18)

30.5
+/- 6.269

30.3
+/- 6.091

32.3
+/- 5.531

ASA 1

0%
n=0

4.2%
n=1

0%
n=0

ASA 2

75%
n=18

75%
n=18

72%
n=13

ASA 3

25%
n=6

21%
n=5

28%
n=5

WHITE

45.8%
n=11

33.3%
n=8

44.4%
n=8

BLACK/AFRICAN AMERICAN

33.3%
n=8

41.7%
n=10

16.7%
n=3

ASIAN/PACIFIC

4.2%
n=1

4.2%
n=1

5.6%
n=1

ASIAN INDIAN

4.2%
n=1

0%
n=0

5.6%
n=1

CHINESE

0%
n=0

4.2%
n=1

0%
n=0

12.5%
n=3

16.7%
n=4

27.8%
n=5

ASA STATUS (%[N])

RACE (%[N])

OTHER RACE

ETHNICITY (%[N])
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NON-HISPANIC

87.5%
n=21

75.0%
n=18

77.8%
n=14

MEXICAN

4.2%
n=1

4.2%
n=1

5.6%
n=1

PUERTO RICAN

8.3%
n=2

4.2%
n=1

5.6%
n=1

CENTRAL-SOUTH AMERICAN

0%
n=0

0%
n=0

5.6%
n=1

OTHER HISPANIC

0%
n=0

16.7%
n=4

5.6%
n=1

WEIGHT (MEAN/SD)

86.4 kg
+/- 22.27

93.8 kg
+/- 19.95

90.3 kg
+/- 22.10

BMI(MEAN/SD)

32.3
+/- 7.34

35.9
+/- 7.28

36.9
+/- 8.63

HYPERTENSION

4.2%
n=1

12.5%
n=3

5.6%
n=1

PREECLAMPSIA

0%
n=0

8.3%
n=2

5.6%
n=1

GESTATIONAL DIABETES

0%
n=0

4.2%
n=1

0%
n=0
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Table 3. One-Way ANOVA
ANOVA
F

CHANGE IN BLOOD PRESSURE BASELINE
- 5 MINUTES POST SPINAL SYSTOLIC

Between Groups

CHANGE IN BLOOD PRESSURE BASELINE
- 5 MINUTES POST SPINAL DIASTOLIC

Between Groups

CHANGE IN BLOOD PRESSURE BASELINE
- 5 MINUTES POST SPINAL MAP

Between Groups

CHANGE IN BLOOD PRESSURE BASELINE
- 15 MINUTES POST SPINAL SYSTOLIC

Between Groups

CHANGE IN BLOOD PRESSURE BASELINE
- 15 MINUTES POST SPINAL DIASTOLIC

Between Groups

0.558

0.575

CHANGE IN BLOOD PRESSURE BASELINE
- 15 MINUTES POST SPINAL MAP

Between Groups

0.472

0.626

CHANGE IN BLOOD PRESSURE BASELINE
- 30 MINUTES POST SPINAL SYSTOLIC

Between Groups

CHANGE IN BLOOD PRESSURE BASELINE
- 30 MINUTES POST SPINAL DIASTOLIC

Between Groups

CHANGE IN BLOOD PRESSURE BASELINE
- 30 MINUTES POST SPINAL MAP

Between Groups

Notes: *Kruskal-Wallis Test Value

1.388

Sig.

0.257

0.215*

1.354

0.266

0.939*

0.308*

1.873

0.162

0.621*
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Table 4. Kruskal-Wallis Test
HYPOTHESIS TEST SUMMARY
Null Hypothesis

Test

Sig.

Test Statistic

Decision

1

The distribution of
Total Ephedrine Dose
Used mg is the same
across categories of
Groups.

Independent-Samples
Kruskal-Wallis Test

0.426

1.706

Retain the null hypothesis.

2

The distribution of
Total Phenylephrine
Dose Used mcg is the
same across categories
of Groups.

Independent-Samples
Kruskal-Wallis Test

0.057

5.739

Retain the null hypothesis.
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Table 5. Blood Pressure Descriptives
BLOOD PRESSURE DESCRIPTIVES
N

CHANGE IN BLOOD PRESSURE
BASELINE - 5 MINUTES POST
SPINAL SYSTOLIC

CHANGE IN BLOOD PRESSURE
BASELINE - 5 MINUTES POST
SPINAL DIASTOLIC

CHANGE IN BLOOD PRESSURE
BASELINE - 5 MINUTES POST
SPINAL MAP

CHANGE IN BLOOD PRESSURE
BASELINE - 15 MINUTES POST
SPINAL SYSTOLIC

Mean

Std. Deviation

≤ 15 minutes

24

0.17

16.730

> 15 minutes and ≤ 30 minutes

24

5.33

23.450

> 30 minutes

18

10.61

19.626

Total

66

4.89

20.291

≤ 15 minutes

24

-3.71

21.523

> 15 minutes and ≤ 30 minutes

24

0.54

26.425

> 30 minutes

18

7.44

18.312

Total

66

0.88

22.769

≤ 15 minutes

24

-2.88

16.783

> 15 minutes and ≤ 30 minutes

24

4.58

22.388

> 30 minutes

18

6.28

19.535

Total

66

2.33

19.825

≤ 15 minutes

24

1.50

19.113

> 15 minutes and ≤ 30 minutes

24

-1.79

22.124

> 30 minutes

18

2.33

16.168

Total

66

0.53

19.341

≤ 15 minutes

24

-0.71

19.666
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CHANGE IN BLOOD PRESSURE
BASELINE - 15 MINUTES POST
SPINAL DIASTOLIC

CHANGE IN BLOOD PRESSURE
BASELINE - 15 MINUTES POST
SPINAL MAP

CHANGE IN BLOOD PRESSURE
BASELINE - 30 MINUTES POST
SPINAL SYSTOLIC

CHANGE IN BLOOD PRESSURE
BASELINE - 30 MINUTES POST
SPINAL DIASTOLIC

CHANGE IN BLOOD PRESSURE
BASELINE - 30 MINUTES POST
SPINAL MAP

> 15 minutes and ≤ 30 minutes

24

-0.71

19.947

> 30 minutes

18

4.67

13.933

Total

66

0.76

18.282

≤ 15 minutes

24

0.08

18.594

> 15 minutes and ≤ 30 minutes

24

-3.13

19.398

> 30 minutes

18

2.06

12.827

Total

66

-0.55

17.407

≤ 15 minutes

24

3.71

14.424

> 15 minutes and ≤ 30 minutes

24

7.58

16.940

> 30 minutes

18

6.67

21.077

Total

66

5.92

17.156

≤ 15 minutes

24

4.71

17.213

> 15 minutes and ≤ 30 minutes

24

3.79

15.970

> 30 minutes

18

13.11

16.761

Total

66

6.67

16.868

≤ 15 minutes

24

4.08

14.166

> 15 minutes and ≤ 30 minutes

24

4.46

15.374

45
> 30 minutes

18

9.83

15.459

Total

66

5.79

14.947
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Table 6. Vasopressor Descriptives
VASOPRESSOR DESCRIPTIVES
GROUPS

≤ 15 MINUTES

Total Ephedrine Dose Used mg

Total Phenylephrine Dose Used
mcg

2.71

346.04

24

24

Std.
Deviation

5.706

423.246

Mean

2.29

177.08

24

24

Std.
Deviation

5.706

132.681

Mean

6.11

499.22

18

18

Std.
Deviation

9.934

695.996

Mean

3.48

326.38

66

66

7.177

461.469

Mean

N

> 15 MINUTES AND ≤ 30
MINUTES

N

> 30 MINUTES

N

TOTAL

N
Std.
Deviation
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Appendix A
DNP Team and Project Implementation Form
University of Pennsylvania
School of Nursing
Doctor of Nursing Practice Program
DNP Team and Project Implementation Form
This form is to be completed by the student(s), institutional/organization project member(s), and
school of nursing project lead and submitted for approval to the DNP Program Director.
--------------------------Student Name: Matthew Rowley and Spenser Zaharie
Project Title: Does Administration Timing of Ondansetron, a 5-HT3 Receptor Antagonist,
Affect Inhibition of the Bezold-Jarisch Reflex in OB C-section Patients Receiving Spinal
Anesthesia
School of Nursing DNP Project Faculty Lead: Dr. Susan Renz
Institutional/Organization DNP Project Member(s): Nicholle Giberson

I hereby accept the following proposed project pending IRB approval (completed by student[s]):
Project Site: Atlanticare Regional Medical Center
Project Purpose: To determine whether the timing of ondansetron has a significant effect
on vasopressor usage and hypotension in elective cesarean section patients receiving spinal
anesthesia at ARMC
Project Activities: Retrospective chart review, analysis of evidence, and dissemination of
results
Participants (Describe target group; approximate # in project): 2
Site(s) Support (Resources):Nicholle Giberson
Data Management Plan: Data will be stored on Matthew Rowley’s University of
Pennsylvania’s School REDCap account. Access will be available to Spenser Zaharie, Dr.
Susan Renz
Anticipated Start Date: 1/31/2021
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Anticipated End Date: 4/30/2021
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Appendix B
Project Charter
AIM
To determine optimal ondansetron administration timing to attenuate hypotension and vasopressor need in
obstetric patients undergoing elective cesarean section.

PROBLEM
Up to 80% of non-pretreated cesarean section patients undergoing spinal anesthesia will present with maternal
hypotension.

IMPORTANCE
Maternal hypotension can lead to cardiovascular collapse in the parturient, as well as decreased perfusion and
APGAR scores for the infant. Research suggests that prophylactic ondansetron administration prior to spinal
anesthesia can decrease the incidence of maternal hypotension. Through optimization of ondansetron timing
greater attenuation of maternal hypotension and decreased vasopressor administration may be achieved. Due to
retrospective chart audit methods proposed, there is no direct risks to patients for this project.

EXPECTED OUTCOMES
The expected outcome will be evaluation of the retrospective chart audit data. Data will be used to determine if
there is significant variability in response to different ondansetron administration times.

MEASURES
Patient data will be taken from CERNER Power Chart. Patients will be separated into different groups based on
ondansetron administration timing. Measures will include systolic, diastolic, and mean arterial blood pressure, as
well as total vasopressor usage for the procedure. Data will be entered and double checked simultaneously by
both Spenser Zaharie and Matthew Rowley.

RISKS/BARRIERS
Challenges may include getting Cerner Power Chart access for Spenser Zaharie, a non-employee at the site.
Cohort discovery is a potential barrier to successfully completing the project but can be mitigated by consultation
with Informatics at the site. Other risks include patient privacy and HIPAA violation with identifiable data
aggregation. Data protection plans are in place. IRB guidance for HIPAA relative to the project will be attended
to and maintained.

STAKEHOLDERS
Key stakeholders include all ARMC elective cesarean section patients without contraindications to ondansetron,
ARMC anesthesia practitioners, and ARMC pre-operative RN’s.
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SCOPE
In Scope:

Out of Scope:

All ARBC OB department patients receiving
ondansetron prior to spinal administration prior to
elective cesarean section, without vasopressor
infusions.

ARMC OB patients having non-elective/emergent
cesarean section procedures.

SCHEDULE
IRB approval will be obtained by January 31st 2021. A two month chart review will be accomplished
February 1st 2021 through March 31st 2021. Analysis will be conducted following chart audit through
April 2021.
PROJECT TEAM
Matthew Rowley

Co-Lead

Spenser Zaharie

Co-Lead

Dr. Amy Sawyer

Project Faculty Consultant

Dr. Susan Renz

Project Faculty Lead

Dr. Nicholle Giberson

Clinical Coordinator ARMC
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Appendix C
N853 Gantt Chart

